Skip to main content
IRWD logo

IRWD

Ironwood Pharmaceuticals, Inc. Class A

$4.68

0.53%

Trade Ideas Performance

Latest Closed Trade Idea

$4.68

0.53%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

5

Social

36

About

Events of Ironwood Pharmaceuticals, Inc. Class A (IRWD)

Over the past six months, several events impacted Ironwood Pharmaceuticals' stock price: on May 27, 2026, the FDA approved LINZESS for pediatric patients aged 2 and older with functional constipation; on June 15, 2026, the company fully repaid its $200 million 1.5% Convertible Senior Notes due 2026; on August 6, 2026, Ironwood reported strong second-quarter earnings with a 33% revenue rise, initiated its confirmatory Phase III STARS-2 trial for apraglutide, and raised its full-year 2026 financial outlook; on October 16, 2026, Tammi Gaskins was appointed Chief Executive Officer, effective January 1, 2027; and on November 5, 2026, the company reported strong third-quarter earnings, beating analyst estimates, with increased profit and LINZESS U.S. net sales, leading to another raise in full-year 2026 financial guidance.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)